NATCO Pharma Ltd included as defendant in antitrust lawsuit in the US

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) would like to update that Celgene Corporation, Bristol Myers Squibb, Breckenridge Pharmaceutical Inc. and Natco Pharma Ltd. have been named defendants along with others in an antitrust lawsuit in the US by Louisiana Health Service & Indemnity Company D/B/A Blue Cross and Blue Shield of Losisiana and HMO Louisiana Inc., regarding Pomalidomide (POMALYST).

Natco believes this matter is without merit. Breckenridge is the ANDA holder and distribution partner for the generic product in the US.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 913.60 as compared to the previous close of Rs. 895.30. The total number of shares traded during the day was 52098 in over 1605 trades.

The stock hit an intraday high of Rs. 928.45 and intraday low of 897.05. The net turnover during the day was Rs. 47953101.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 AntiTrust Lawsuit US Pomalidomide